Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidaxomicin vs Vancomycin for CDI with Concomitant Antibiotics
NCT02692651Phase 4Completed
- Sponsor
- University of Michigan
- Start
- May 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fidaxomicin in Clostridioides difficile infection (CDI) (2 arms), sponsored by University of Michigan. Primary endpoint: Clinical Cure: Resolution of Diarrhea at 86 days. Started May 2017; status: completed.
02
Drugs
fidaxomicin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02692651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692651.